Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
601-620 of 991 trials

Pancreatic Exocrine Insufficiency: Creon® Therapy

We are studying how well Creon® helps patients with pancreatic exocrine insufficiency after surgery. The goal is to see if it improves symptoms and nutritional health.

Pancreatic Exocrine Insufficiency6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyInternal Medicine

Cirrhosis Due to NASH/MASH: Efruxifermin Study

We are testing a new medication, Efruxifermin, for people with compensated cirrhosis from NASH/MASH. The study aims to see if it improves liver health and reduces related health risks compared to a placebo.

Non-Alcoholic Steatohepatitis (NASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH)>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementEndocrinologyHepatology

Multiple Sclerosis: ABP 692 vs. Ocrevus

We are comparing a new treatment called ABP 692 with Ocrevus for people with relapsing-remitting multiple sclerosis. The goal is to see how they differ in effectiveness and safety.

Relapsing-Remitting Multiple Sclerosis>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

EGL-001 for Advanced Solid Tumors

We are testing a new treatment called EGL-001 in adults with advanced or metastatic solid tumors. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Advanced and Metastatic Solid Tumors1-2 yearsSafety phase (I)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Breast Cancer: PF-07220060 with Letrozole

We are studying a new medicine, PF-07220060, combined with letrozole for adults with HR-positive, HER2-negative advanced breast cancer. This trial compares its effectiveness to standard treatments in patients who haven't had prior systemic therapy.

Advanced/Metastatic Breast CancerConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Menstrual Migraine: Atogepant Study

We are testing Atogepant to see if it can help prevent menstrual migraines. The study will also look at its safety and how well people tolerate the treatment.

Menstrual Migraine6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementGynecology and ObstetricsNeurology

Ovarian Cancer: Continued Treatment with Olaparib

We are providing ongoing treatment with Olaparib for patients who have benefited from it in a previous study. This trial focuses on monitoring safety while allowing continued access to the medication.

Ovarian CancerBreast CancerProstate Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

ENPP1 Deficiency: INZ-701 Study

We are investigating whether the drug INZ-701 can help infants with ENPP1 deficiency by improving survival and preventing heart and respiratory problems. The study aims to see if it can also support physical growth and reduce artery issues.

Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Non-Small Cell Lung Cancer: Acasunlimab and Pembrolizumab Study

We are evaluating a new combination treatment for patients with advanced non-small cell lung cancer who have already received other therapies. The goal is to see if this combination works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Targeted Therapies for Moderate to Severe Crohn’s Disease

We are studying new targeted treatments for adults with moderate to severe Crohn’s disease. The goal is to evaluate their safety and effectiveness in managing this condition.

Crohn's Disease3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Ulcerative Colitis: RO7790121 Treatment Study

We are studying a new treatment for people with moderately to severely active ulcerative colitis to see if it can help induce remission. The trial will also assess its safety and impact on symptoms and quality of life.

Ulcerative ColitisConfirmation phase (III)Post-Trial Drug AccessCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Mucosal Melanoma: Anti-PD1 Immunotherapy Study

We are investigating whether a new treatment combining anti-PD1 therapy with surgery improves disease-free survival in patients with resectable mucosal melanoma. This study aims to evaluate the effectiveness and safety of this approach.

Melanoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Invasive Aspergillosis: Olorofim vs. AmBisome®

We are studying a new treatment called olorofim for patients with invasive aspergillosis to see if it works better and is safer than the standard treatment, AmBisome®. This trial will also look at how these treatments affect patients' quality of life.

Invasive Fungal Infection3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Psychosis in Alzheimer's: ITI-1284 Study

We are evaluating a new medication, ITI-1284, for treating psychosis in patients with Alzheimer's disease. The study aims to see if it is more effective than a placebo in improving symptoms.

Psychosis associated with Alzheimer’s Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPsychiatry

Bipolar Mania: Lumateperone Study

We are evaluating the safety and effectiveness of lumateperone for treating manic episodes in patients with bipolar I disorder. This study compares the medication to a placebo to see how well it works.

Bipolar Disorder≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPsychiatry

Crohn's Disease: RO7790121 Treatment Study

We are evaluating a new treatment for people with moderately to severely active Crohn's disease to see if it helps improve symptoms and quality of life compared to a placebo.

Moderately to Severely Active Crohn's DiseaseConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Metastatic Non-Small Cell Lung Cancer: Ivonescimab vs Pembrolizumab

We are studying whether ivonescimab combined with chemotherapy helps patients with metastatic non-small cell lung cancer live longer and manage their disease better than pembrolizumab with chemotherapy.

Metastatic Non-small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

MEN1703 for Aggressive B-cell Non-Hodgkin Lymphoma

We are studying the safety and effectiveness of MEN1703 alone and with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. This research aims to find better treatment options for this challenging cancer.

Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Psoriatic Arthritis: Zasocitinib Study

We are testing a new medication, Zasocitinib, for people with active psoriatic arthritis to see if it improves symptoms better than a placebo. The study also looks at how it affects daily life and physical function.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementRheumatology

HER2-Positive Gastric Cancer: Trastuzumab Deruxtecan Study

We are testing a new treatment combining Trastuzumab Deruxtecan with chemotherapy for patients with advanced HER2-positive gastric or GEJ cancer. The goal is to see if this combination works better than the current standard treatment.

Metastatic Gastric Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology